Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$196.00
|
|
Trading Report for (ABT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Abbott Laboratories Confirms FY 2012 EPS Guidance
Abbott Laboratories announced that it is confirming its ongoing earnings-per-share guidance for fiscal 2012 of $5.00 to $5.10, reflecting another year of expected strong performance. . According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $5.04 for fiscal 2012.
Latest Developments for Abbott Laboratories
- Russia Rejects Abbott Laboratories Plan To Buy Petrovax-Reuters
- Abbott Laboratories Announces FDA Approval And U.S. Launch Of TECNIS Toric Intraocular Lens For Cataract Patients
- Abbott Laboratories Issues Q2 2013 EPS Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Guidance
- Pfizer Inc, Novartis AG And Abbott Laboratories Weigh Bids For Brazil's Ache Laboratorios Farmaceuticos-Reuters
- Share this
- Link this
- Digg this
Follow Reuters